Pfizer hikes prices for 100 prescription drugs by an average 9%

Pfizer has increased prices for 100 drugs, including Viagra, by an average of 9 percent, according to The Financial Times. The move from America’s largest pharmaceutical company, which took effect July 1, came just a month after President Donald Trump addressed drug costs, saying the industry would voluntarily slash prices.

Pfizer increased the price of Viagra by nearly 20 percent, with an average wholesale price of a 100 mg pill jumping to $88.45 from $73.85 at the start of the year. The price of Chantix, a popular smoking-cessation medication, has increased 17 percent in 2018.

Pfizer acknowledged the price increases, while noting it decrease price tags on five medications by 16 to 44 percent.

“The list price remains unchanged for the majority of our medicines. We are modifying prices for about 10 percent of our medicines, including some instances where we’re decreasing the price,” the company said in a statement.

But the summer increase could engender a public backlash. While pharma companies traditionally raised prices twice yearly, some have moved to an annual hike amid growing political pressure.

In May, Trump outlined a general plan to control price inflation by negotiating with pharma companies, controlling prices overseas and attacking pharmacy benefit managers, or PBMs. While his rhetorical has been incendiary—he said pharma companies are “getting away with murder” during the 2016 campaign—his proposals were, for the most part, limited in scope.

“We are not going to reward companies that constantly raise prices, which, in the past, has been most companies,” Trump said. “Frankly, Alex used to run one of them, so nobody knows the system better than Alex. That’s what we needed.”

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup